CRIS Stock Summary and Trading Ideas (Curis | NASDAQ:CRIS)

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis trades on the NASDAQ stock market under the symbol CRIS.

As of September 21, 2026, CRIS stock price declined to $0.97 with 162,400 million shares trading.

CRIS has a beta of 4.71, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.04 to the broad based SPY ETF.

CRIS has a market cap of $2.36 million. This is considered a Sub-Micro Cap stock.

Last quarter Curis reported $0 in Revenue and -$4.02 earnings per share. This fell short of revenue expectation by $-750,000 and exceeded earnings estimates by $1.29.

In the last 3 years, CRIS traded as high as $17.49 and as low as $.18.

The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VXF, VTI.

CRIS has underperformed the market in the last year with a price return of -43.3% while the SPY ETF gained +18.5%. However, in the short term, CRIS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +131.5% vs +3.8% return in SPY. But in the last 2 weeks, CRIS shares have been beat by the market, returning -27.8% compared to an SPY return of +0.7%.

CRIS support price is $.94 and resistance is $1.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.